It is very important for us to protect ourselves, we need medicine and vaccines. They work by helping our bodies learn how to safely ward off diseases. When you get a vaccine, this is intended to avoid catching certain illnesses that can do harm. But traditional ways of making vaccines have always been slow and expensive. This can lead to shortages or at least make it difficult for those who need vaccines to get them. Fortunately, there is a new and improved way to produce vaccines: with the help of certain bacteria (E.coli).
Tech: VLP technology was used as the standardized method by scientists. This type of vaccine is named VLP which stands for Virus-Like Particles. The way this is done codes for vaccines that mimic viruses so our bodies can recognize these and then learn to outpace them. E.coli lives in our stomachs and breaks down some of the food, but it can also be coax to make these vaccines.
To begin, scientists inserted a fragment of the virus's own genetic blueprints into E.coli bacteria. That genetic code instructs bacteria to make something that closely resembles the virus. The approach coaxes the bacteria to assemble virus-like particles (VLPs) that resemble the actual pathogen but are not infectious. They then purify these VLPs to make sure that they are safe and can be included in the vaccine.
E.coli bacteria are modified in the laboratory so that they can only produce the virus-like particles. Bacteriologists culture these bacteria under optimal conditions and carefully managed environments so that they remain viable in good health. That means the vaccine made from these germs or harmful materials will not make us ill.
Synthetic VLPs are made in this process, With the help of E.coli it is a way more faster and cost effective method for scientists. This is certainly a faster way of creating vaccines than old methods, which required animal cells and were extremely complex. The Old ways will make vaccine in months or even years, this is not good because people were dying.
Introduction of E.coli technology in vaccine production has revolutionised the health sector, especially during pandemics. This also makes vaccines cheaper to produce, faster and easier. This new approach also enables the creation of vaccines for previously difficult to vaccinate-against diseases, such as some particularly complex viruses.
Virus like particle production using E.coli: The Namedoji technology is based on the efficient expression of self-assembling VLPs in bacteria for development as vaccine against influenza, Ebola and human papilloma viruses. These vaccines protect people against diseases. The technology has also played a big role in producing the Covid-19 vaccines that have been key to ending this pandemic and saving lives.
Yaohai Bio-Pharma, a leader in CDMOs for microbial biologics, is located in Jiangsu. We are focusing on microbially produced therapeutics and vaccines that are VLP Vaccine Production in E. coli for human, veterinary as well as pet health management. We have the most cutting-edge RD platforms as well as manufacturing technology that cover the entire manufacturing process, from microbial strain development, cell banking, process and method development to clinical and commercial manufacture which ensures successful production of novel solutions. We have gained an extensive amount of experience in bio processing of microbial cells. More than 200 projects have been successfully completed, and we support our clients in get through regulations, such as those of US FDA as well as EU EMA. We also aid them with Australia TGA and China NMPA. Our experience and professional knowledge as well as our extensive knowledge allow us to quickly respond to market demands and provide customized CDMO services.
Yaohai BioPharma, a top 10 Microbial CDMO that integrates quality management and regulatory affairs. Our quality system that is compliant with current GMP standards as well as international regulations. Our team of regulatory experts is proficient in global regulatory frameworks to accelerate biological launches. We ensure traceable production procedures quality products, as well as conformity with the requirements of the VLP Vaccine Production in E. coli and EU EMA. Australia TGA and China NMPA are also met. Yaohai BioPharma successfully passed an in-person audit conducted by a Qualified Person of the European Union (QP) to examine our GMP system and production facility. We also completed the initial certification audits of the ISO9001 Quality Management System and ISO14001 Environmental Management System.
Yaohai Bio-Pharma, a top 10 producer of biological products, is a specialist in microbial fermentation. We have established an advanced facility that is equipped with modern facilities and strong RD manufacturing capabilities. We have five drug substance manufacturing lines that are in compliance with GMP requirements for microbial fermentation and purification, as well as two fill-finish lines that are automated for cartridges, vials, as well as pre-filled syringes. The available fermentation scales vary from 100L to 500L, 1000L and 2000L. VLP Vaccine Production in E. coli for vias are 1ml to 25ml, whereas the pre-filled syringes and cartridge filling specifications cover 1-3ml. Our production workshop is cGMP compliant and guarantees steady supply of clinical samples as well as commercial items. Our plant produces large molecules which are shipped to the globe.
Yaohai Bio-Pharma has experience in the production of biologics created from VLP Vaccine Production in E. coli. We offer customized RD and manufacturing solutions while making sure that there are no risks. We have been involved in diverse modalities such as subunit vaccines recombinant, peptides hormones, cytokines, growth factors, single-domain antibodies enzymes, plasmid DNA MRNA, and many more. We are a specialist in many microorganisms, including yeast extracellular and intracellular secretion (yields up to 15g/L) as well as bacteria intracellular soluble and inclusion body (yields as high as 10g/L). We have also created a BSL-2 fermentation platform to create bacterial vaccines. We focus on improving processes, increasing product yields, and reducing production costs. Utilizing a strong technology team, we can ensure prompt and reliable project delivery that will bring your product to market faster.